StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Keros Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -698.0%. For fiscal 2025 it was 27.7%, against -112543.7% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202527.7%+112571.4
FY2023Dec 31, 2023-112543.7%−112263.2
FY2021Dec 31, 2021-280.5%−174.8
FY2019Dec 31, 2019-105.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-80865.6%−80937.6
Q4 FY2025Dec 31, 2025-7702.6%+24783.4
Q3 FY2025Sep 30, 2025-108.9%+540891.1
Q2 FY2025Jun 30, 2025-219.2%−194.8
Q1 FY2025Mar 31, 202572.0%+15613.0
Q4 FY2023Dec 31, 2023-32486.0%−32376.9
Q3 FY2023Sep 30, 2023-541000.0%−540907.0
Q4 FY2021Dec 31, 2021-24.3%+81.7
Q2 FY2021Jun 30, 2021-15541.0%−15426.7
Q4 FY2019Dec 31, 2019-109.1%–
Q3 FY2019Sep 30, 2019-93.0%–
Q2 FY2019Jun 30, 2019-106.0%–
Q1 FY2019Mar 31, 2019-114.3%–

More Keros Therapeutics figures

See a number that looks wrong?